No Data
No Data
Dongyao Pharmaceutical (1875.HK) 2024 interim performance release conference
Dongyao Pharmaceutical (1875.HK) will hold its 2024 interim performance conference in Hong Kong at 14:30 on August 14, 2024.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Dongyao Pharmaceutical-B(01875.HK) plans to hold a board of directors meeting on August 13th to approve its mid-term performance.
Dongyao Pharmaceutical-B (01875.HK) announced that the company will hold a board of directors meeting on Tuesday, August 13, 2024 to consider and approve the interim performance of the group for the six months ended June 30, 2024, as well as to handle other matters.
Shareholders May Not Be So Generous With TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation And Here's Why
Dongyao Pharmaceutical-B (01875.HK) proposes to adopt the 2024 Restricted Share Award Scheme
Gelonghui, May 29丨Dongyao Pharmaceutical-B (01875.HK) issued an announcement. The board of directors recommended the adoption of the 2024 restricted share award plan, which is valid for ten (10) years from the date of adoption. This will enable the company to attract and retain necessary talents, motivate group employees, and enable the company to flexibly grant share-based rewards on existing shares in addition to new shares.
TOT BIOPHARM International Company Limited (HKG:1875) Soars 28% But It's A Story Of Risk Vs Reward
No Data